1 September 2024

Appendix 4C - Quarterly Cashflow Report

Melbourne Australia:  Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2012.

The cash balance at 31 December 2012 was $33.2 million.  The cash balance excludes the Company’s anticipated R&D tax incentive refund of $5.3 million receivable this financial year.

Total operating and investing cash outflows for the quarter were $4.4 million.  The cash burn for the quarter is in line with expectations, with the outflows largely relating to the two bacterial vaginosis (BV) clinical programs for VivaGel®  (treatment and prevention of recurrence).  A significant proportion (>50%) of the Company’s YTD cash flow is attributable to the non-recurrent costs for these two clinical programs and this expenditure is eligible for a 45% rebate under the R&D Tax Incentive program.  Results of Starpharma’s Phase 2 clinical trial of VivaGel® for the prevention of recurrence of BV are expected in Q1 2013.

 

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 109kb)

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.